Lantus is the best-selling diabetes drug in the world right now and the top-selling drug for Sanofi. But the drug goes off patent in 2015, so the French drugmaker is coming on strong with its Lantus successor, known as U300.
Sanofi has peeled back the cover on another chapter of Phase III data for U300, advancing its case that its next-gen diabetes therapy can be safer and just as effective as its blockbuster Lantus as it sets the stage for a regulatory pitch next year. But analysts may be left wondering if the long-acting insulin can successfully beat back rivals with a better set of data.
With generics flooding the market, U.S. drug spending fell by about 2% last year. That took pressure off of health insurers and left room for drug price hikes by those companies with drugs in demand, like insulin. Novo Nordisk is one of those companies.
CHICAGO-- Sanofi has provided the first glimpse at Phase III data for new insulin glargine, which is a next-generation version of its top-selling diabetes drug Lantus.
The prevalence of diabetes is growing globally, and with that the size of the diabetes drug market. But the market has gotten increasingly competitive and increasingly complex. All of the top 10 best-selling drugs in the diabetes category are blockbusters, according to EvaluatePharma. So who makes them? Check out the report >>
With competition fierce in the diabetes category, Sanofi is pushing its franchise in multiple directions, issuing new devices, new drugs and new markets to secure its position.
As a major medical meeting brings the spotlight to new diabetes drugs this month, Sanofi has begun reaching out to the media to secure center-stage status for data on its new therapies. The French drug giant has a next-generation version of its best-selling insulin drug Lantus as well as a combo therapy that have implications for its future in the market.
WIth Sanofi riding the tail end of the latest earnings wave, its sales and profits shortfall feels like more of the same. It hasn't been a good quarter for Big Pharma, and Sanofi's results fall right in line with the rest. Its 5.3% sales drop was less severe than most, while its profits suffered a bit more, with a 34% decline.
When can a drugmaker beat earnings expectations and project a 10% boost in profits for the year and still end up disappointing investors? When that drugmaker is Novo Nordisk, the world's largest insulin maker, focused on a rapidly growing treatment area with investors expecting more, more, more.
As new diabetes drug Tresiba inches its way toward approval, Novo Nordisk and rival Sanofi have put up dueling studies and generated dueling headlines. But their rivalry extends beyond those two headlining drugs, Bloomberg reports.